These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26712687)

  • 1. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
    Schreibelt G; Bol KF; Westdorp H; Wimmers F; Aarntzen EH; Duiveman-de Boer T; van de Rakt MW; Scharenborg NM; de Boer AJ; Pots JM; Olde Nordkamp MA; van Oorschot TG; Tel J; Winkels G; Petry K; Blokx WA; van Rossum MM; Welzen ME; Mus RD; Croockewit SA; Koornstra RH; Jacobs JF; Kelderman S; Blank CU; Gerritsen WR; Punt CJ; Figdor CG; de Vries IJ
    Clin Cancer Res; 2016 May; 22(9):2155-66. PubMed ID: 26712687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
    Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
    Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
    Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
    Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
    J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
    Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
    Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
    Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
    Schuler-Thurner B; Schultz ES; Berger TG; Weinlich G; Ebner S; Woerl P; Bender A; Feuerstein B; Fritsch PO; Romani N; Schuler G
    J Exp Med; 2002 May; 195(10):1279-88. PubMed ID: 12021308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
    Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
    Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
    Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
    J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
    Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F
    Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.